A detailed history of Goldman Sachs Group Inc transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 108,661 shares of STTK stock, worth $120,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108,661
Previous 93,499 16.22%
Holding current value
$120,613
Previous $360,000 5.28%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.0 - $4.85 $45,486 - $73,535
15,162 Added 16.22%
108,661 $379,000
Q2 2024

Aug 13, 2024

SELL
$3.56 - $11.18 $586,118 - $1.84 Million
-164,640 Reduced 63.78%
93,499 $360,000
Q1 2024

May 15, 2024

BUY
$7.37 - $10.09 $1.79 Million - $2.46 Million
243,354 Added 1645.95%
258,139 $2.31 Million
Q4 2023

Feb 13, 2024

BUY
$1.37 - $7.24 $20,255 - $107,043
14,785 New
14,785 $105,000
Q1 2023

May 14, 2024

SELL
$2.5 - $4.72 $10,980 - $20,730
-4,392 Reduced 29.25%
10,621 $31,000
Q1 2023

May 11, 2023

SELL
$2.5 - $4.72 $10,980 - $20,730
-4,392 Reduced 29.25%
10,621 $31,000
Q4 2022

May 14, 2024

SELL
$1.96 - $3.26 $12,973 - $21,577
-6,619 Reduced 30.6%
15,013 $34,000
Q4 2022

Feb 13, 2023

SELL
$1.96 - $3.26 $12,973 - $21,577
-6,619 Reduced 30.6%
15,013 $34,000
Q3 2022

May 14, 2024

SELL
$2.6 - $5.52 $26,257 - $55,746
-10,099 Reduced 31.83%
21,632 $58,000
Q3 2022

Nov 10, 2022

SELL
$2.6 - $5.52 $26,257 - $55,746
-10,099 Reduced 31.83%
21,632 $0
Q2 2022

May 14, 2024

BUY
$2.7 - $4.59 $45,754 - $77,782
16,946 Added 114.62%
31,731 $129,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $4.59 $185,284 - $314,984
-68,624 Reduced 68.38%
31,731 $129,000
Q1 2022

May 16, 2022

BUY
$4.22 - $8.89 $134,162 - $282,630
31,792 Added 46.37%
100,355 $428,000
Q4 2021

Feb 14, 2022

BUY
$8.36 - $21.08 $434,979 - $1.1 Million
52,031 Added 314.73%
68,563 $583,000
Q3 2021

Nov 10, 2021

BUY
$17.57 - $28.95 $290,467 - $478,601
16,532 New
16,532 $337,000

Others Institutions Holding STTK

About Shattuck Labs, Inc.


  • Ticker STTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,382,000
  • Market Cap $47M
  • Description
  • Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...
More about STTK
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.